BridgeMD
Tests treatment safety and results for Myopia
Official title Assessment of the Efficacy and Safety of a DYnaMic Peripheral DegradatiON Myopia Disorder Control in Myopic Children ״DYMOND Study״
ClinicalTrials.gov ID: NCT07390500
What this study is testing
- What it's testing
- The DYMOND study evaluates the safety and effectiveness of TrackSight™, a digital medical application designed to slow myopia (nearsightedness) progression in children during everyday screen use. TrackSight uses eye-tracking technology to keep central vision clear while subtly adjusting the image in the peripheral viewing area, based on established scientific principles known to influence eye growth.
- Phase 2: a mid-size study of how well it works
- Time commitment: about 12 months
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 6 to 12
You may be able to join if
- Aged 6-12 years -. Diagnosed with myopia: cycloplegic spherical or spherical equivalent (SER) between -0.75D and -5.00D, astigmatism ≤ -1.50D...
- Visual acuity 20/32 or better (age-appropriate testing) in both eyes
- Interocular VA difference ≤1.00 logMAR line
- Subject in general good health and able, as per investigator decision, to comply with study visits and protocol procedures
- The subject is using digital devices for at least 1 hour/day regularly according to parental report
You likely can't join if
- Past or concurrent use of any other myopia treatment (e.g., atropine, orthokeratology, myopia control glasses/lenses)
- Eye diseases or abnormality, developmental conditions, or past ocular surgeries or any other condition which could potentially affect refraction or...
- Current or prior history of manifest strabismus, amblyopia, or nystagmus
- Subject cannot pass eye tracking calibration in at least 50% of cases, or cannot be tracked in at least 50% of the time during a screening...
- Current or previous use of bifocal lenses, progressive-addition lenses, or multi-focal contact lenses
- Premature gestational age ≤32 weeks or birth weight \<1500g.
See the full eligibility criteria
- Aged 6-12 years -. Diagnosed with myopia: cycloplegic spherical or spherical equivalent (SER) between -0.75D and -5.00D, astigmatism ≤ -1.50D, anisometropia \< 1.50D
- Visual acuity 20/32 or better (age-appropriate testing) in both eyes
- Interocular VA difference ≤1.00 logMAR line
- Subject in general good health and able, as per investigator decision, to comply with study visits and protocol procedures
- The subject is using digital devices for at least 1 hour/day regularly according to parental report
- Signed informed consent by legal parent/guardian and assent approval -. Currently wearing single vision refractive correction
- Past or concurrent use of any other myopia treatment (e.g., atropine, orthokeratology, myopia control glasses/lenses)
- Eye diseases or abnormality, developmental conditions, or past ocular surgeries or any other condition which could potentially affect refraction or AL progression according to the investigator's judgement
- Current or prior history of manifest strabismus, amblyopia, or nystagmus
- Subject cannot pass eye tracking calibration in at least 50% of cases, or cannot be tracked in at least 50% of the time during a screening eligibility test
- Current or previous use of bifocal lenses, progressive-addition lenses, or multi-focal contact lenses
- Premature gestational age ≤32 weeks or birth weight \<1500g.
The study team makes the final eligibility decision.
Where it's taking place
- Rehovot, Israel
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The study runs about 12 months per participant, based on its public description. The team confirms the exact schedule and number of visits before you enroll.
Who can join this trial?
This study is enrolling all sexes, 6 years to 12 years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Rehovot, Israel. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.